CAEL-101 not checked

Alexion Pharmaceuticals, Inc. · Ch mAb 11-1F4

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
None yet
 
Trials
2 active
4 in total · 2 in the EU
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“The investigational product, CAEL-101, is formulated as a sterile liquid solution of protein plus excipients for dilution in a single-use, stoppered, glass vial. Each 10 mL vial contains 300 mg of CAEL-101 at a concentration of 30 mg/mL. CAEL-101 will be diluted with commercially available 0.9% Normal Saline.”In the company’s words, NCT04512235 on ClinicalTrials.gov
Tested for
AL Amyloidosis (2 trials)
Main trialPhase 3
“AL (or light chain) amyloidosis begins in the bone marrow where abnormal proteins misfold and create free light chains that cannot be broken down. These free light chains bind together to form amyloid fibrils that build up in the extracellular space of organs, affecting the kidneys, heart, liver, spleen, nervous system and digestive tract. The primary purpose of this study is to determine whether CAEL-101, a monoclonal antibody that removes AL amyloid deposits from tissues and organs, improves overall survival, reduces cardiovascular related hospitalizations and it is safe and well tolerated…”In the company’s words, NCT04512235 on ClinicalTrials.gov
Other names
Anselamimab · Ch mAb 11-1F4

Other drugs for AL Amyloidosis

All 13 drugs for AL Amyloidosis

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials4

TrialPhaseCompletesWhat it tests
Phase 3Active, not recruiting 8 Apr 2025 A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)
Phase 3Active, not recruiting 10 May 2025 A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES)
Phase 2Completed 14 Nov 2023 A Study to Evaluate the Safety and Tolerability of CAEL-101 in Patients With AL Amyloidosis
Phase 1Completed 13 Jul 2017 Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients With AL Amyloidosis
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow CAEL-101

Following is part of Solo: you see every change to CAEL-101 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in